Can Novel Anticoagulants Reduce Thrombosis Without Increasing Bleeding – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Surasak Wichaiyo, published in Journal of Thrombosis and Haemostasis, adding:
“Pharmacology of anticoagulants: from heparin to novel target-specific agents.
This review delineates the pharmacology of currently available anticoagulants (heparins, warfarin, and direct oral anticoagulants) alongside investigational agents.
Factor XI and factor XII inhibitors emerge as targets that may uncouple antithrombotic efficacy from bleeding risk, with several FXI inhibitors now in phase II and III trials.”
Title: Pharmacology of anticoagulants: from heparin to novel target-specific agents
Authors: Surasak Wichaiyo
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 14:44Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month
-
Sep 7, 2026, 18:25David Akande: Things I Wish People Knew About Sickle Cell
-
Sep 7, 2026, 18:24Prachi Bansal: A Small Act of Giving, A Lifelong Lesson in Humanity
-
Sep 7, 2026, 17:27Isaac Okello: From Global Dialogue to Local Impact in Sickle Cell Disease